BioPharma Credit deploys another $125 million into a pre-approval biotech. But the company it just backed is the one whose stock fell more than 50% on its Phase 3 data.
In the period after a trial succeeds, when the data are in, the FDA submission is about to happen, the company needs capital to cross the finish line. Pharmakon Advisors, the specialist lender behind BioPharma Credit (LSE: BPCR), last week deployed another $125 million into that sort of gap, this time backing Zenas BioPharma, a clinical-stage autoimmune company weeks away from filing for its first FDA approval .
The deal, announced via RNS on March 17, 2026, is a senior secured loan agreement for up to $125 million from BioPharma Credit, with a matching investment of up to an additional $125 million from BioPharma Credit Investments V (Master) LP — two vehicles managed by the same Pharmakon team — for a total potential facility of $250 million . According to the filing, the facility is structured across five tranches. The first tranche of $37.5 million from BioPharma Credit’s share is to be funded ten business days after the execution of the agreement, with the remainder available through April 2029, contingent on regulatory approvals and commercial milestones . The loan matures in March 2031 and carries interest at three-month SOFR plus 5.75%, with a 3.25% SOFR floor.
Earlier in March, we reported that Pharmakon increased its loan to UroGen Pharma from $125 million to $250 million on the back of the commercial launch of ZUSDURI, a newly approved bladder cancer treatment. The Zenas deal follows along: a company at the regulatory threshold, a multi-tranche facility, and Pharmakon positioned as the senior secured creditor ahead of any equity dilution. The difference this time is that the clinical picture is considerably more complicated.
The drug and the data
Zenas’s lead asset, obexelimab, is a bifunctional monoclonal antibody designed to suppress B cell activity across multiple autoimmune diseases without depleting those cells entirely . In January 2026, Zenas reported Phase 3 results from the INDIGO trial in IgG4-Related Disease — a rare inflammatory condition in which immune cells infiltrate and damage organs including the pancreas, kidneys, and salivary glands. Obexelimab met the primary endpoint, demonstrating a statistically significant 56% reduction in the risk of IgG4-RD flare compared to placebo over a 52-week period (Hazard Ratio 0.44, p=0.0005), and met all four key secondary endpoints . Zenas anticipates submitting a BLA to the FDA in the second quarter of 2026 and an MAA to the EMA in the second half of the year. Bristol Myers Squibb holds commercialization rights for obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia .
On the surface, it seemed clear. In practice, it wasn’t as clear. Zenas shares fell more than 50% on the day the data were released. The 56% flare reduction, while statistically significant, appeared to fall short of what at least one Wall Street analyst considered necessary for commercial viability, especially considering that Amgen’s Uplizna, approved for IgG4-RD in April 2025, reduced flares by 87% in its own pivotal clinical testing. The stock dropped 51.86%, or $17.89 per share, to close at $16.61 on January 5, 2026. The following day, the CEO acknowledged on a conference call that the company was “disappointed that the hazard ratio doesn’t hit a number that many people were hoping for,” leading to a further decline Cross-trial comparisons are methodologically imperfect, but the competitive benchmark is now established and it is a high one.
That is the context in which Pharmakon just structured a $250 million loan.
Why lend into a 50%+ stock drop
The answer could be in how Pharmakon sees what the risk is. As a senior secured creditor, Pharmakon is not betting on the stock price. It is betting on whether the company generates enough revenue, from any approved product, to service and repay a loan. A 56% reduction in flare risk in a rare disease with no FDA-approved treatment until last year is still a meaningful clinical result. Furthermore, Zenas reported it had $360.5 million in cash as of December 31, 2025 , suggesting the Pharmakon facility is not emergency financing but rather commercial preparation capital, that funds a commercial launch infrastructure before the first prescription is written.
Zenas also carries a second asset. Orelabrutinib is a BTK inhibitor being developed for progressive multiple sclerosis. That is a larger market with significant unmet need. Zenas is conducting a global Phase 3 trial in primary progressive multiple sclerosis and expects to initiate another in non-active secondary progressive MS . Pharmakon’s loan is secured against a pipeline, not just a single asset.
The pattern
BioPharma Credit has now deployed or committed substantial capital into two pre-revenue or early-revenue biotechs within weeks. One is UroGen in the bladder cancer space and now Zenas in autoimmune disease. Both deals share the same architecture: senior security, multi-tranche disbursement tied to regulatory and commercial gates, and a maturity date far enough out to allow commercial ramp. Pharmakon is not a venture lender taking binary clinical risk. It is a commercial bridge lender that moves in once the clinical risk has been substantially resolved, and prices accordingly.
For BPCR shareholders, the question is whether the Zenas bet is as well-constructed as the UroGen one. UroGen had an approved product generating $109.8 million in annual revenue in 2025 when Pharmakon increased its commitment . Zenas has a Phase 3 result that spooked equity markets and an FDA submission that has not yet been filed. The loan covenants and milestone conditions, detailed in the March 17 RNS filing, will be the real indicator of how tightly Pharmakon has structured its downside protection here.